Pfizer Inc. Q2 FY2026 income statement | sankey.it

PFEQ2 FY2026

Pfizer Inc.

USD, quarter ended 2026-06-28

Operating Expenses: R&D 19% | SG&A 23% of revenue

Other Expense: Actual other expense was $5.4B

Revenue

$15.0B+2.6%

Gross margin

72.8%+8.5 pts

Operating margin

31.3%+6.9 pts

Net margin (loss)

-1.6%-21 pts

Open full screen

Revenue segments

No segment breakdown available for this filing - the flow shows revenue narrowing straight into cost and profit.

Period history

Revenue, by quarter

Income statement

Line	Q2 FY2026	YoY
Revenue	$15,034,000,000	+2.6%
Cost of revenue	$4,092,000,000	-22%
Gross profit	$10,942,000,000	+16%
Operating expenses	$6,236,000,000	+6.7%
Operating income	$4,706,000,000	+32%
Other income/expense, net	-$5,359,000,000	-909%
Income before tax

More in Healthcare

LLY+48%Q2 FY2026

Eli Lilly and Company

Fiscal period end: June 28, 2026
Source: Financial Modeling Prep, via the DATA project
Diagram generated: September 3, 2026